It has been demonstrated that in alcohol-dependent men the uHex test is one of the most powerful discriminating tools, while uGGT has a discriminating power similar to that of sHex but worse than that of uHex, sGGT and s%CDT. Receiver Operating Characteristic (ROC) areas under the curves (AUC) for uHex, uGGT, s%CDT, sHex and sGGT were 0.92, 0.79, 0.88, 0.79 and 0.92, respectively. Due to their good parameters, low cost, ease of use and non-invasive character the uHex and uGGT tests are useful tools for the detection of chronic alcohol abuse.

The usefulness of beta-hexosaminidase (uHex) and gamma-glutamyltransferase (uGGT) activity in urine as markers of chronic alcohol abuse was examined in male methadone programme participants. The group consisted of 24 non-abusing and 21 alcohol-abusing men. It has been demonstrated that the uHex test is one of the best alcohol abuse markers for opiate-dependent individuals (Receiver Operating Characteristic (ROC) area under the curve (AUC) 0.82, sensitivity 0.70, specificity 0.82). The uGGT test can be used as a marker of alcohol abuse in opiate-dependent men, however, its parameters are worse than those of uHex (ROC AUC 0.73, sensitivity 0.71, specificity 0.77). Among serum markers, only the relative amount of carbohydrate-deficient transferrin (s%CDT) has parameters sufficient for diagnostic use (ROC AUC 0.74, sensitivity 0.60, specificity 0.86). Factors other than alcohol can render the commonly used sGGT and sHex tests useless (differences between means for abusing and abstinent patients were insignificant, AUC ROC were lower than 0.7-0.65 and 0.69, respectively). Their good parameters, low costs, ease of use and non-invasive character are all features which make uHex and uGGT highly useful tools in the detection of chronic alcohol abuse in opiate-dependent patients participating in a methadone substitution programme.

No abstract

Twenty-six patients diagnosed as chronic schizophrenics were given injections of zuclopenthixol decanoate (cis(Z)-clopenthixol decanoate) 200 mg every 3 weeks for at least 6 months. Before treatment and on each day of injection the patients' mental state was assessed by Brief Psychiatric Rating Scale (BPRS), 18 items. A registration of side effects and basal laboratory data was also performed. Blood samples were drawn on each day of injection before injection and 3-7 days after injection (time of maximum concentration). Neuroleptic activity, which was considered equivalent to the concentration of zuclopenthixol, was determined in serum by radio-receptor assay (RRA). Based on amelioration scores greater than or equal to 50% on the BPRS, 15 patients were characterized as responders and 11 as non-responders. The responder group showed a statistically significant reduction in BPRS score, whereas this was not the case for the non-responders. Apart from a few patients, the serum concentrations showed a low intra-individual variation, but a relatively high inter-individual variation. The responder group had a significantly higher mean pre-injection concentration than the non-responder group, whereas no significant difference was found in day 3-7 concentrations. The fluctuation of the serum concentration expressed as the ratio between maximum (days 3-7) and minimum (pre-inj.) was found to be significantly lower for responders than for non-responders. Thus although the present study did not demonstrate a clear relationship between serum level and clinical effect, it indicates that the best antipsychotic effect is obtained with a serum concentration which fluctuates only slightly (the ratio max/min concentration not exceeding 2.1).

No abstract